Assessment of DNA damage-repair capacity in systemic lupus erythematosus patients as a potential biomarker of response to cyclophosphamide.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12620001287921

Enrollment

Registered

2020-11-27

Start date

2020-10-19

Completion date

2022-10-20

Last updated

2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Cyclophosphamide is one of several medications that may be used to help to treat damage to the kidney that can occur in some patients with systemic lupus erythematosus (lupus nephritis). Unfortunately treatment with cyclophosphamide is not always successful in every patient. Cyclophosphamide works by killing the over-active immune cells which are causing inflammation in the kidney. Recent international research suggests that, compared with healthy volunteers, immune cells from patients with lupus have a decreased ability to repair the type of damage caused by drugs like cyclophosphamide. We want to investigate whether a test using cells collected from a blood sample can detect this type of decreased repair activity.

Interventions

The study involves collection of a single blood sample from patients diagnosed with systemic lupus erythematosus. Information on age, gender, self-identified ethnicity will be collected as well as data from the medical notes about recent lab-test results on lupus, kidney function and medications received as part of routine care. This is a single observation at this one timepoint.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

>18 years of age Diagnosed with lupus nephritis Able to give informed consent Not currently receiving cyclophosphamide or other alkylating agent

Exclusion criteria

Not able to provide a blood sample Currently taking cyclophosphamide or other alkylating agent

Outcome results